Over the last year; however, positive results of phase 2 interventional trials have been announced which support the complement system as a drug target in the treatment of geographic atrophy: APL, a C3 inhibitor developed by Apellis Pharmaceuticals, Inc (NCT03525600 and NCT03525613) and Zimura, a C5 inhibitor, developed by Iveric bio, formerly Ophthotech Corporation (NCT02686658). The gene discussed is C3; the disease is atrophic macular degeneration.